Cancer Chemotherapy and Pharmacology

, Volume 33, Supplement 1, pp S79–S83 | Cite as

Combination therapy consisting of arterial infusion chemotherapy (EPF, EAP) and transcatheter arterial embolization (TAE)

  • Hiraku Yodono
  • Shoichi D. Takekawa
  • Koji Tarusawa
  • Isao Ikami
  • Jiro Kanehira
  • Yoko Saito
  • Satoshi Takahashi
  • Taisuke Sasaki
  • Naoko Nishi
  • Tamaki Kimura
  • Shigeo Oikawa
  • Koichi Shibutani
  • Atsushi Shinohara
  • Akira Anbai
  • Rikako Sasaki
  • Yukio Sasaki
  • Hiroshi Noda
Clinical Aspects in the Treatment for Operable and Session II. Chemotherapy and Radiotherapy II. 1. TAE-1 Hepatocellular Carcinoma, Arterial Infusion Chemotherapy, Transcatheter Arterial Embolization

Abstract

From January 1988 to January 1993, 45 patients with unresectable advanced hepatocellular carcinoma (HCC) were treated with a new combination therapy consisting of arterial infusion chemotherapy and TAE. The combination therapy was performed according to our treatment schedule as follows: two courses of arterial infusion chemotherapy were given first, and then transcatheter arterial embolization (TAE) using a mixture of Lipiodol and cisplatin powder was performed. Two arterial infusion chemotherapeutic regimens were employed: EPF (etoposide, cisplatin, and 5-fluorouracil) and EAP (etoposide, Adriamycin or Epi-adriamycin, and cisplatin). The anticancer drugs were infused through a catheter inserted into the proper or common hepatic artery. Assessment was made of the anticancer effect and survival rate of each treatment method. The response to each therapy was evaluated on the basis of CT performed prior to and after the treatment. In the EPF·TAE group, the response rate was about 46%, whereas in the EAP·TAE group it was 48%. Overall, 21 of 45 patients attained a regression rate of 50% or more. Furthermore, daughter nodules decreased in size or disappeared in about 67% of 15 patients. Additionally, tumor thrombi tended to show a similar response. In all of the cases, the average duration of survival was 30.3 months, and the 1-year survival value was 68%, the 2-year survival value was 44%, and the 3-year survival value was 35%. These results were superior to those obtained with TAE therapy alone.

Keywords

Catheter Hepatocellular Carcinoma Etoposide Hepatic Artery Anticancer Drug 

References

  1. 1.
    Japan Society for Cancer Therapy (1986) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy (in Japanese). J Jpn Soc Cancer Ther 21: 929Google Scholar
  2. 2.
    Liver Cancer Study Group of Japan (1987) The general rules for the clinical and pathological study of primary liver cancer (in Japanese). Kanehara & Co., TokyoGoogle Scholar
  3. 3.
    Melia WM, Johnson PJ, Williams R (1983) Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with Adriamycin. Cancer 51: 206Google Scholar
  4. 4.
    Nagasue N, Yukaya H (1989) Liver resection for hepatocellular carcinoma: results from 150 consecutive patients. Cancer Chemother Pharmacol 23 [Suppl]: S78Google Scholar
  5. 5.
    Nakamura K, Takashima S, Takada K, Fujimoto K, Kaminou T, Nakatsuka H, Minakuchi K, Onoyama Y (1992) Clinical evaluation of intermittent arterial infusion chemotherapy with an implanted reservoir for hepatocellular carcinoma. Cancer Chemother Pharmacol 31 [Suppl I]: S93Google Scholar
  6. 6.
    Quinn JJ, Altman AJ, Robinson T, Cooke RW, Hight DW, Foster JH (1985) Adriamycin and cisplatin for hepatoblastoma. Cancer 56: 1926Google Scholar
  7. 7.
    Sakurai M, Okamura J, Kuroda C (1984) Transcatheter chemoembolization effective for treating hepatocellular carcinoma. Cancer 54: 387Google Scholar
  8. 8.
    Sugiura N, Takara K, Ohto M, Okuda K, Hirooka N (1983) Percutaneous intratumoral injection of ethanol under ultrasound imaging for treatment of small hepatocellular carcinoma. Acta Hepatol Jpn 24: 920Google Scholar
  9. 9.
    Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148: 397Google Scholar
  10. 10.
    Yodono H, Saito Y, Saikawa Y, Midorikawa H, Yokoyama Y, Takekawa SD (1989) Combination chemoembolization therapy for hepatocellular carcinoma mainly using cisplatin (CDDP). Cancer Chemother Pharmacol 23 [Suppl]: S42Google Scholar
  11. 11.
    Yodon H, Tarusawa K, Sasaki T, Kanehira J, Saito Y, Takahashi S, Kimura T, Nishi N, Nakamura Y, Takekawa SD (1989) A case with hepatocellular carcinoma effectively treated by intra-arterial infusion of CDDP and other agents. Jpn J Cancer Chemother 16: 3265Google Scholar
  12. 12.
    Yodono H, Sasaki T, Tarusawa K, Midorikawa H, Saito Y, Takekawa SD (1992) Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPF and EAP therapies. Cancer Chemother Pharmacol 31 [Suppl I]: S89Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • Hiraku Yodono
    • 1
  • Shoichi D. Takekawa
    • 1
  • Koji Tarusawa
    • 1
  • Isao Ikami
    • 1
  • Jiro Kanehira
    • 1
  • Yoko Saito
    • 1
  • Satoshi Takahashi
    • 1
  • Taisuke Sasaki
    • 1
  • Naoko Nishi
    • 1
  • Tamaki Kimura
    • 1
  • Shigeo Oikawa
    • 1
  • Koichi Shibutani
    • 1
  • Atsushi Shinohara
    • 1
  • Akira Anbai
    • 1
  • Rikako Sasaki
    • 1
  • Yukio Sasaki
    • 1
  • Hiroshi Noda
    • 1
  1. 1.Department of RadiologyHirosaki University HospitalHirosakiJapan

Personalised recommendations